...
首页> 外文期刊>Colorectal cancer. >Interview: Future of immunotherapy for colorectal cancer
【24h】

Interview: Future of immunotherapy for colorectal cancer

机译:访谈:大肠癌免疫疗法的未来

获取原文
   

获取外文期刊封面封底 >>

       

摘要

John Marshall speaks to Ruth Williamson, Commissioning Editor: John Marshall is a global leader in the research and development of drugs for colon cancer and other gastrointestinal cancers. He is the clinical director of oncology for Georgetown University Hospital (Washington, DC, USA), associate director for clinical care of the Lombardi Comprehensive Cancer Center (Washington, DC, USA) and chief of the Division of Hematology-Oncology, Georgetown University Hospital. He is widely published in the field of clinical oncology, and is the principal investigator of over 150 clinical trials, at both local and national levels. In 2009, Marshall became the founding director of the Otto J Ruesch Center for the Cure of Gastrointestinal Cancer (Washington, DC, USA) and for over a decade he has directed Lombardi’s Developmental Therapeutics Program, while also maintaining his regular clinical practice. His own research focuses on the development of a novel vaccine for the treatment of advanced colon cancer.
机译:约翰·马歇尔(John Marshall)与委托编辑露丝·威廉姆森(Ruth Williamson)对话:约翰·马歇尔(John Marshall)是结肠癌和其他胃肠道癌药物研发的全球领导者。他是乔治敦大学医院(美国华盛顿特区)的肿瘤学临床主任,伦巴第综合癌症中心(美国华盛顿特区)的临床护理副主任以及乔治敦大学医院血液肿瘤科的负责人。他在临床肿瘤学领域被广泛发表,并且是150多个地方和国家级临床试验的主要研究者。 2009年,马歇尔(Marshall)成为奥托·鲁斯(Otto J Ruesch)胃肠道疾病治疗中心(美国华盛顿特区)的创始董事,在指导伦巴第的发展治疗计划十多年的同时,他还保持了常规的临床实践。他自己的研究专注于开发用于治疗晚期结肠癌的新型疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号